1 Abstract
Aim The aim of this study was to estimate the household transmissibility of SARS-CoV-2 for lineage B.1.1.7 compared with other lineages, by age and viral load. Further-more, we wanted to estimate whether there is a multiplicative or additive effect of the increased transmissibility of B.1.1.7 compared with other lineages.
Background New lineages of SARS-CoV-2 are of potential concern due to higher transmissibility, risk of severe outcomes, and/or escape from neutralizing antibodies. Lineage B.1.1.7 has been estimated to be more transmissible than other previously known lineages, but the association between transmissibility and risk factors, such as age of primary case and viral load is still unknown.
Methods We used comprehensive administrative data from Denmark, comprising the full population, all SARS-CoV-2 RT-PCR tests, and all WGS lineage data (January 11 to February 7, 2021), to estimate household transmissibility stratified by lineage B.1.1.7 and other lineages.
Results We included 5,241 households with primary cases; 808 were infected with SARS-CoV-2 lineage B.1.1.7 and 4,433 were infected with other lineages. The attack rate was 38% in households with a primary case infected with B.1.1.7 and 27% in households with a primary case infected with other lineages. Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other lineages. The increased transmissibility of B.1.1.7 was multiplicative across age and viral load.
Conclusions The results found in this study add new knowledge that can be used to mitigate the further spread of SARS-CoV-2 lineage B.1.1.7, which is becoming increasingly widespread in numerous countries. Our results clarify that the transmissibility of B.1.1.7 should be included as a multiplicative effect in mathematical models used as a tool for decision makers. The results may have important public health implications, as household transmission may serve as a bridge between otherwise separate transmission domains, such as schools and physical workplaces, despite implemented non-pharmaceutical interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Frederik Plesner Lyngse: Independent Research Fund Denmark (Grant no. 9061-00035B.); Novo Nordisk Foundation (grant no. NNF17OC0026542); the Danish National Research Foundation through its grant (DNRF-134) to the Center for Economic Behavior and Inequality (CEBI) at the University of Copenhagen. Laust Hvas Mortensen: Novo Nordisk Foundation (NNF17OC0027594, NNF17OC0027812). Carsten Thure Kirkeby: None. Robert Leo Skov: None. Kåre Mølbak: None. Nina Ruth Steenhard: None. Lasse Engbo Christiansen: None. Marianne Voldstedlund: None. Camilla Holten Møller: None. Jannik Fonager: None. Tyra Grove Krause: None. Thomas Yssing Michaelsen: None. Mads Albertsen: Poul Due Jensen Fonden (Corona Danica); Styrelsen for Forskning og Uddannelse, Forskning i COVID-19 (0238-00002B Forståelse af smitteveje gennem sekventering og analyse af coronavirus genomer). Morten Rasmussen: None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted on administrative register data. According to Danish law, ethics approval is not needed for such research. All data management and analyses were carried out on the Danish Health Data Authority's restricted research servers with project number FSEID-00004942. The publication only contains aggregated results and no personal data. The publication is, therefore, not covered by the European General Data Protection Regulation.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Statens Serum Institut and The Danish Health Data Authority.
